{
    "clinical_study": {
        "@rank": "156519", 
        "arm_group": {
            "arm_group_label": "Fostamatinib Disodium", 
            "arm_group_type": "Experimental", 
            "description": "Fostamatinib Disodium tablet 100 mg or 150 mg by mouth twice a day"
        }, 
        "brief_summary": {
            "textblock": "The purpose of this study is to determine whether fostamatinib is safe and effective in\n      treating patients with persistent/chronic Immune Thrombocytopenic Purpura  (ITP) over a 2\n      year period."
        }, 
        "brief_title": "Open Label Study of R788 in the Treatment of Persistent/Chronic Immune Thrombocytopenic Purpura (ITP)", 
        "completion_date": {
            "#text": "October 2017", 
            "@type": "Anticipated"
        }, 
        "condition": "Immune Thrombocytopenic Purpura", 
        "condition_browse": {
            "mesh_term": [
                "Purpura", 
                "Purpura, Thrombocytopenic", 
                "Purpura, Thrombocytopenic, Idiopathic"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Completed Week 24 evaluation of Study C935788-047 or Study C935788 048\n\n          -  Able and willing to give written informed consent\n\n        Exclusion Criteria:\n\n          -  Discontinued participation in Study C935788-047 or Study C935788-048 for any reason\n             other than lack of response\n\n          -  Poorly controlled hypertension during Study C935788-047 or Study C935788-048\n\n          -  Significant infection, an acute infection such as influenza, or known inflammatory\n             process"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "150", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "February 27, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02077192", 
            "org_study_id": "C-935788-049", 
            "secondary_id": "2013-005454-30"
        }, 
        "intervention": {
            "arm_group_label": "Fostamatinib Disodium", 
            "description": "Fostamatinib Disodium tablet 100 mg or 150 mg by mouth twice a day", 
            "intervention_name": "Fostamatinib Disodium", 
            "intervention_type": "Drug", 
            "other_name": [
                "R935788", 
                "R788", 
                "Fostamatinib"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "February 28, 2014", 
        "number_of_arms": "1", 
        "official_title": "A Phase 3 Open Label Extension Study of Fostamatinib Disodium in the Treatment of Persistent/Chronic Immune Thrombocytopenic Purpura", 
        "overall_contact": {
            "email": "alowe@rigel.com", 
            "last_name": "Ann Lowe, MD", 
            "phone": "512.502.5353"
        }, 
        "overall_official": {
            "affiliation": "Rigel Pharmaceuticals, Inc.", 
            "last_name": "Ann Lowe, MD", 
            "role": "Study Director"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": [
                "United States: Food and Drug Administration", 
                "Austria: Agency for Health and Food Safety", 
                "Bulgaria: Bulgarian Drug Agency", 
                "Canada: Health Canada", 
                "Czech Republic: State Institute for Drug Control", 
                "Denmark: Danish Health and Medicines Authority", 
                "France: Agence Nationale de S\u00e9curit\u00e9 du M\u00e9dicament et des produits de sant\u00e9", 
                "Germany: Federal Institute for Drugs and Medical Devices", 
                "Hungary: National Institute of Pharmacy", 
                "Italy: The Italian Medicines Agency", 
                "Netherlands: Medicines Evaluation Board (MEB)", 
                "Poland: Office for Registration of Medicinal Products, Medical Devices and Biocidal Products", 
                "Spain: Spanish Agency of Medicines", 
                "United Kingdom: Medicines and Healthcare Products Regulatory Agency"
            ], 
            "has_dmc": "No"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "October 2017", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Number of Participants with  platelet count of at least 50,000/\u00b5L as a Measure of Safety and Efficacy", 
            "safety_issue": "Yes", 
            "time_frame": "2 years"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02077192"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Rigel Pharmaceuticals", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Rigel Pharmaceuticals", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "July 2014", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "February 2014"
    }
}